Compare FORTY & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | VCEL |
|---|---|---|
| Founded | 1985 | 1989 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 1998 | 1996 |
| Metric | FORTY | VCEL |
|---|---|---|
| Price | $117.51 | $43.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | 406.0 | ★ 461.2K |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | $36.65 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $102.01 | $28.95 |
| 52 Week High | $190.56 | $49.32 |
| Indicator | FORTY | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 54.31 | 42.23 |
| Support Level | $115.00 | $32.44 |
| Resistance Level | $119.68 | $49.04 |
| Average True Range (ATR) | 0.45 | 1.43 |
| MACD | 1.61 | -0.35 |
| Stochastic Oscillator | 78.82 | 24.30 |
Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.